The Food and Drug Administration has released the final form of its Risk Evaluation and Mitigation Strategies, or REMS, for extended-release and long-acting opioids. The 20 companies that manufacture these drugs, whose misuse and abuse of ER/LA opioids has become so widespread that related overdoses, addiction, and deaths now constitute a public health crisis, are now required to educate prescribers on their appropriate use. The final REMS includes the “Blueprint for Prescriber ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only unlock thePrinter-friendly, you'll also gain access to exclusive premium content.

Already registered? here.